ARTICLE | Management Tracks
Daly to succeed McEnany as Catalyst CEO
Plus: Hennemand joins Covant as CEO and updates from Invitae, Immunome, Antiva, Omeros, Actimed and RegCell
October 21, 2023 12:29 AM UTC
Richard Daly will succeed Patrick McEnany as CEO of neurological and epileptic disease company Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), effective Jan. 1. Daly was president of CARsgen Therapeutics Holdings Ltd. (HKEX:2171) and COO at BeyondSpring Inc. (NASDAQ:BYSI). McEnany, who founded Catalyst and is retiring as CEO, will remain chairman.
Covalent drug discovery company Covant Therapeutics Inc. named Vincent Hennemand as CEO. Hennemand was COO at Intergalactic Therapeutics Inc. Covant was incubated by Roivant Sciences Ltd. (NASDAQ:ROIV)...